Identification of antigenic determinants of the polar immune response in leprosy may illuminate both protection and pathogenesis. Thirty subjects were studied (22 with polar disease and 8 healthy controls who were heavily exposed but disease-free) by assaying the proliferative, interferon (IFN)-g, and antibody responses to recombinant antigens of Mycobacterium leprae (10, 28, 36, and 65 kDa). The 10-kDa antigen elicited IFN-g production from all tuberculoid (TT) and borderline tuberculoid (BT) patients but little from controls, lepromatous (LL), or borderline lepromatous (BL) patients ( ). Production of 65-kDa-specific IFN-g was P ! .05 higher in TT/BT than in controls or LL/BL patients ( ). All subjects produced 65-P ! .006 kDa-specific antibody, but it was higher in LL/BL patients than in healthy controls, whose responses were higher than in TT/BT subjects ( ). The 36-kDa antibody responses P ϭ .035 were selectively increased in LL/BL subjects ( ). The intermediate phenotype of the P ! .02 controls suggests that M. leprae-specific production of IFN-g may contribute to pathology and to protection in leprosy.
A number of Mycobacterium leprae genes have been cloned and sequenced [3] . In this study, we examined the cellular and antibody responses to 4 major recombinant proteins, an obvious approach, but one rarely undertaken [4, 5] . The 10-kDa GroES protein is a major target of the T cell rather than the antibody response [6] . The cytoplasmic 28-kDa protein is a target of M. leprae-specific T cell clones and is recognized by sera of LL/BL patients [7] . The 36-kDa antigen is a prominent target of the antibody response [8] . The 65-kDa GroEL equivalent is a major immunogen and has been widely studied (reviewed in [3] ).
Materials and Methods
Subjects. We recruited 22 leprosy patients (19 men, 3 women; average age, 36.1 years, range, 20-55) from the Central Jalma Institute for Leprosy, Agra, India. All diagnoses were biopsy confirmed and classified as TT (3), BT (8) , LL (5), or BL (6) according to the criteria of Ridley and Jopling [1] . All patients had received !4 weeks of World Health Organization (WHO) multidrug chemotherapy. Eight healthy endemic controls (4 men and 4 women; average age, 44.1 years, range, 33-55) were recruited from indigenous staff who had worked in the same institute and had remained leprosy-free for a mean of 15.7 years.
Recombinant antigens. M. leprae soluble extract (MLSE) was a gift of R. J. W. Rees (WHO protein bank, Braunschweig, Germany). The recombinant antigens (WHO protein bank) were prepared as previously described [6, 9, 10] . Residual endotoxin contamination (10 kDa, 1094 pg/mg; 28 kDa, 0.17 pg/mg; 36 kDa, 357 pg/mg; and 65 kDa, 19 pg/mg) was reduced by the inclusion of 10 mg/mL polymyxin B in stock solutions. We used the following doses of antigen in culture: 10, 28, and 36 kDa, 5 mg/mL; 65 kDa and MLSE, 1 mg/mL. Purified protein derivative (PPD; Evans Medical, Liverpool, UK) was used at 10 U/mL.
Proliferative and interferon (IFN)-g assay. These assays were performed as previously described [11] . Peripheral blood mononuclear cells (PBMC) were isolated and cultured in RPMI 1640 (Gibco, Paisley, UK) at cells/well in triplicate in the pres- 5 ϫ 10 assayed by sandwich ELISA using anti-IFN-g monoclonal antibody (MAb) 1-DIK at 2.5 mg/mL (Mabtech, Nacka, Sweden) for coating and biotinylated detection MAb 7B-61 anti-IFN-g at 1 mg/ mL.
IgG antibody ELISA. We coated Maxisorp (Nunc, Roskilde, Denmark) plates overnight at 4ЊC with 50 mL of antigen in PBS at 5 mg/mL for 10-, 36-, and 65-kDa proteins and 25 mg/mL for the 28-kDa protein and MLSE. The wells were blocked in PBS/ 0.05% Tween 20/5% milk for 1 h at room temperature. Serum (100 mL) diluted in blocker was added to duplicate wells with and without antigen at 1/20, 1/100, 1/500, 1/2500, 1/12,500, and 1/62,500 dilutions. After incubation for 2 h at 37ЊC, the plates were washed 5 times. We added 100 mL of horseradish peroxidase-conjugated anti-IgG antibody (Sigma, St. Louis), and the plates were incubated for 1 h at room temperature and then washed 5 times. After the addition of 150 mL of K-Blue substrate (ELISA Technologies, Lexington, KY), the plates were read in a spectrophotometer at 680 nm. The maximum dilution of serum giving an optical density increment of у0.1 D ODU in the presence of antigen was calculated from the individual curves and is expressed in the results as the maximum antibody titer.
Results
The cell proliferation, IFN-g, and antibody responses for each subject group are shown in table 1. Both healthy controls and TT/BT subjects had strong proliferative responses to MLSE, whereas the response of LL/BL patients was depressed (
). The production of IFN-g was highest in the TT/BT P ! .007 group ( vs. LL/BL), although 6 of 7 healthy controls P ϭ .003 responded less strongly. In comparison, the antibody response of LL/BL subjects was much higher ( ) than that of P ! .02 healthy controls or TT/BT subjects, although nearly all healthy controls and 5 of 11 TT/BT patients had some response. Although no single antigen gave rise to as strong a response as MLSE in any assay, there were interesting differences between antigens.
The 10-kDa antigen elicited IFN-g production from all TT/ BT subjects but not from healthy controls or LL/BL patients. The magnitude of antibody response to this antigen was low in all groups. The 65-kDa antigen elicited a more mixed re- sponse. Although the IFN-g response of the TT/BT group was again significantly higher than that of healthy controls or LL/ BL subjects ( ), the latter groups had greater CMI than P ! .006 to the 10-kDa antigen. In addition, there was antibody production in all groups. For instance, the response of LL/BL patients, although higher, was not significantly different from that of healthy controls ( ), whose responses were sig-P ϭ .137 nificantly higher than those of TT/BT subjects ( ). The P ϭ .035 36-kDa antigen stimulated relatively low-magnitude T cell responses in all groups, but a selective high titer antibody response in LL/BL subjects ( ). The 28-kDa protein was P ! .02 only a moderate stimulator of the T cell response, and there was no significant difference among groups. Only 2 of 30 persons studied had antibody titers 11/50. The CMI to PPD was included for comparison. There was no significant difference between healthy controls and TT/BT subjects, but both the proliferative and IFN-g responses of LL/BL subjects were depressed ( ) by comparison. P ! .02 Despite the clear differences between subject groups, there was a poor correlation between individual proliferative, IFNg, and antibody titers in response to all antigens. The best relationship was between the proliferative and antibody responses to MLSE, which showed the expected inverse correlation ( , ; figure 1 ). Figure 1 shows that TT/ r ϭ Ϫ0.53 P ! .01 BT persons tended to have a low antibody and high proliferative response, LL/BL subjects had the opposite pattern, and healthy controls were intermediate in phenotype. However, variation within groups was nearly as great as between them.
Because both TT and LL leprosy are associated with HLA-DRB1*15 (reviewed in [12] ), we DR typed all subjects in this study by polymerase chain reaction using sequence-specific primers. Of 30 subjects, 14 were heterozygous for DRB1*15 (4 healthy controls and 4 TT/BT and 6 LL/BL subjects). Although the small number of subjects studied limits definitive conclusions, no relationship between positivity for this allele and a particular pattern of immune reactivity to any of the recombinant antigens was seen. However, the proliferative response to MLSE was higher in non-DR15 subjects in all groups (median stimulation index by group: healthy controls, 13.6 for Non-DR15, 5.0 for DR15; TT/BT, 12.7 and 10.3 and LL/BL, 4.8 and 2.2, respectively). Conversely, the geometric mean of the antibody titer in LL/BL subjects who were DR15-positive (25,500) was higher than in those who were DR15-negative (1567, ; figure 1 ). P ϭ .028
Discussion
In this study we confirmed the well-recognized observation that TT/BT leprosy is characterized by strong CMI with low antibody production and that the LL/BL form is characterized by depressed CMI and high antibody production. However, there were interesting differences between the antigens. The recombinant 10-kDa antigen stimulated a predominantly cellular response, especially IFN-g in TT/BT leprosy. The 65-kDa antigen stimulated a mixed response, with marked antibody production in LL/BL disease, and was the best stimulator of IFNg production in TT/BT subjects. The 36-kDa antigen was most stimulatory of antibody production in LL/BL subjects, whereas the 28-kDa antigen was poorly stimulatory of both cellular and antibody responses. Unlike Klatser et al. [4] , we found that individual cellular and antibody responses to antigens were poorly correlated, and only the antibody and proliferative response to MLSE showed an inverse correlation (figure 1). Klatser et al. did not report the relationship between immune reactivity and HLA-DR type. In our study there was a trend toward higher antibody production with depressed cell proliferation and IFN-g production in persons bearing the DRB1*15 allele, regardless of disease phenotype. Of interest, DRB1*15-positive persons with pulmonary tuberculosis have an elevated response to the 38-kDa antigen of Mycobacterium tuberculosis [13] . How-ever, a much larger analysis of leprosy patients would be necessary to investigate this phenomenon further.
It is difficult to define a healthy control group in leprosy studies, as there is no reliable means of ascertaining infection and the incubation period can be exceedingly long. None of the recombinant antigens that we studied appeared likely to have useful diagnostic sensitivity. All of our control subjects (mean exposure to leprosy, 15 years) mounted either an antibody or cellular response to MLSE. It is of interest that these arguably immune healthy controls were of intermediate phenotype in our in vitro assays. Compared with the TT/BT subjects, the antibody response of healthy controls to the 65-kDa antigen was higher and the production of IFN-g was lower, especially in response to 10-and 65-kDa antigens. In addition, these differences showed specificity for M. leprae: The IFN-g and cell proliferative responses to PPD were slightly higher in healthy controls than in the TT/BT group (table 1). These findings suggest that healthy controls are protected from leprosy by infection with M. tuberculosis, bacille Calmette-Guérin, or environmental mycobacteria or that a strong type 1 response contributes as much to pathology in TT/BT disease as it does to protection. It would be of interest to determine whether the anti-10-and anti-65-kDa IFN-g response in TT/BT patients was directed mainly toward cross-reactive or M. leprae-specific T cell epitopes. Although both molecules are highly conserved between M. tuberculosis and M. leprae, a T cell stimulatory peptide (p21-35) within the 10-kDa antigen preferentially recognized by patients with quiescent TT/BT leprosy has been recognized [14] . This analysis was based on cell proliferation, an assay we believe to be less discriminatory. It would be useful to determine the frequency of peptide p21-35-responsive IFNg-producing cells (by ELISPOT) in recently diagnosed TT/BT disease and in heavily exposed healthy controls.
Analysis of cytokine gene expression from infected tissue indicates a substantial role for type 1/type 2 T cell subsets in the regulation of the immune spectrum in leprosy, and the response of TT/BT subjects has been suggested as an immune phenotype [2] . Our data and those of others from peripheral blood [15] suggest that the regulation may be more complex. The intermediate immune phenotype of the healthy controls heavily exposed to leprosy in the present study also indicates that, although a polar type 1 response is clearly associated with a reduced bacillary burden in tissues, it may also contribute to the immunopathology characteristic of tuberculoid disease.
